Asia rises, MIT holds Top spot as QS reveals 2026 World University Rankings
US and China gain ground, Italy and Saudi Arabia debut in top 100
#QSWUR
LONDON, June 19, 2025 /PRNewswire/ -- Global higher education experts QS Quacquarelli Symonds have released the 22nd edition of the QS World University Rankings.
MIT retains the global #1 position for the 14th consecutive year. Imperial College London holds second place, while Stanford University surges to third.
Top 10 Universities (2026 / 2025)
1 / 1 MIT – US
2 / 2 Imperial College London – UK
3 / 6 Stanford University – US
4 / 3 University of Oxford – UK
5 / 4 Harvard University – US
6 / 5 University of Cambridge – UK
7 / 7 ETH Zurich – Switzerland
8 / 8 National University of Singapore – Singapore
9 / 9 UCL – UK
10 / 10 California Institute of Technology – US
This edition features 1,500+ institutions across 106 locations. The US leads with 192 ranked universities, followed by the UK (90) and Mainland China (72). India (54) and Germany (48) round out the top five.
Ben Sowter, QS Senior Vice President, said:
'We are witnessing a rebalancing of global academic influence. The Ranking highlights a shifting center of gravity in higher education—towards Asia, which now claims the highest number of ranked universities worldwide. While traditional powerhouses maintain strong positions, the data shows clear momentum in regions investing heavily in research capacity, internationalization, and long-term strategy. The QS World University Rankings illuminate not only institutional excellence, but also the evolving contours of global knowledge production. These shifts underscore an increasingly multipolar academic world—more competitive, more connected, and more ambitious than ever.'
Highlights Asia now leads with 565 ranked universities—more than Europe (487), the Americas (358), Africa (47), and Oceania (44). It also adds the most newcomers: 84, compared to 10 in the Americas, 9 in Europe, 8 in Africa, and 1 in Oceania.
US: Records more institutions improving than declining for the first time in seven years. Stanford rises due to Sustainability and International Faculty metrics. University of Chicago re-enters the top 20.
UK: Matches US with four top-10 entries. Remains a leader in International Student Ratio.
Canada: McGill overtakes Toronto as national leader (27th). Canada excels in Sustainability.
Australia: Two top-20 entries. University of Sydney drops to 25th; 71% of institutions fall.
China: 45% of institutions rise. Tsinghua climbs to 17th; Fudan jumps nine places to 30th.
India: IIT Delhi becomes top-ranked nationally (123rd), overtaking IIT Bombay.
Italy & Saudi Arabia: Enter the top 100 for the first time—Politecnico di Milano (98th), KFUPM (67th).
Africa: South Africa holds top four spots; Cape Town climbs 21 places to 150th.
Logo - https://mma.prnewswire.com/media/2714473/QSWUR_Logo.jpg
View original content to download multimedia: https://www.prnewswire.com/news-releases/asia-rises-mit-holds-top-spot-as-qs-reveals-2026-world-university-rankings-302485769.html
SOURCE QS Quacquarelli Symonds
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Scholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug Trial
We recently published a list of These 10 Stocks Boast Double-Digit Gains Amid Boring Market. Scholar Rock Holding Corporation (NASDAQ:SRRK) is one of the best-performing stocks on Thursday. Scholar Rock jumped by 16.6 percent on Wednesday to close at $36.32 apiece as investor sentiment was bolstered by the positive results from the second phase of its weight loss drug trial. In a statement, Scholar Rock Holding Corporation (NASDAQ:SRRK) said the trial, which aims to assess its drug candidate apitegromab's combination with tirzepatide, was generally well tolerated, leading to higher quality weight loss as compared with taking tirzepatide alone. According to Scholar Rock Holding Corporation (NASDAQ:SRRK), apitegromab therapy in combination with tirzepatide resulted in the preservation of 4.2 pounds of lean mass compared with tirzepatide alone. 'While this is an exciting development for our platform, we remain focused on preparing for the launch of apitegromab, and following its potential approval in SMA, we look forward to studying it in a range of neuromuscular diseases with high unmet need,' said Scholar Rock Holding Corporation (NASDAQ:SRRK) President and CEO Akshay Vaishnaw, adding that he was looking forward to exploring its potential in various rare, severe debilitating neuromuscular disorders. A scientist holding a flask of liquid in a laboratory, highlighting the research and discoveries of new treatments. 'We remain on track to file an IND application for SRK-439 in the second half of this year to support the first in human study,' he said. While we acknowledge the potential of SRRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Wall Street Journal
25 minutes ago
- Wall Street Journal
Trump Says He's Nearing a Possible Deal With Harvard
President Trump said his administration was 'working closely' with Harvard University and could announce a deal within the next week. The White House and Harvard have been locked in battle since late March. Trump has pulled billions in federal funds over antisemitism and DEI concerns, tried to block Harvard's ability to enroll international students and threatened its tax-exempt status. Harvard has sued the administration, saying the government has violated its First Amendment rights.
New York Times
27 minutes ago
- New York Times
People With Severe Diabetes Are Cured in Small Trial of New Drug
A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of type 1 diabetes. One year later, these 10 patients no longer need insulin. The other two patients need much lower doses. The experimental treatment, called zimislecel and made by Vertex Pharmaceuticals of Boston, involves stem cells that scientists prodded to turn into pancreatic islet cells, which regulate blood glucose levels. The new islet cells were infused and reached the pancreas, where they took up residence. The study was presented Friday evening at the annual meeting of the American Diabetes Association and published online by The New England Journal of Medicine. 'It's trailblazing work,' said Dr. Mark Anderson, professor and director of the diabetes center at the University of California in San Francisco. 'Being free of insulin is life changing,' added Dr. Anderson, who was not involved in the study. Vertex, like other drug companies, declined to announce the treatment's cost before the Food and Drug Administration approves it. The treatment, said Vertex spokeswoman Dee Smith, could potentially help all patients with type 1 diabetes, although they would need to weigh the risks against the benefits of possibly not needing insulin. Want all of The Times? Subscribe.
